His primary areas of investigation include Retinal, Cis-trans-Isomerases, Genetic enhancement, Retina and Ophthalmology. Particularly relevant to Retinitis pigmentosa is his body of work in Retinal. Cis-trans-Isomerases is connected with RPE65 and Disease in his research.
Albert M. Maguire has included themes like Leber's congenital amaurosis, Gene therapy of the human retina and Vector in his RPE65 study. His study in Retina is interdisciplinary in nature, drawing from both Genetics and Molecular biology. The study incorporates disciplines such as Optometry, Clinical trial and Surgery in addition to Ophthalmology.
Albert M. Maguire mainly investigates Ophthalmology, Retinal, Genetic enhancement, Retina and Visual acuity. His study on Ophthalmology is mostly dedicated to connecting different topics, such as Surgery. His specific area of interest is Retinal, where Albert M. Maguire studies RPE65.
His Genetic enhancement research integrates issues from Retinal degeneration, Adeno-associated virus, Transgene, Immunology and Viral vector. His studies deal with areas such as Pathology, Anatomy and Cell biology as well as Retina. Albert M. Maguire has researched Visual acuity in several fields, including Visual field, Clinical trial and Randomized controlled trial.
Albert M. Maguire mostly deals with Ophthalmology, Retinal, RPE65, Genetic enhancement and Visual acuity. The Retinal study combines topics in areas such as Orientation, Visual dysfunction and Retina. His RPE65 study combines topics in areas such as Heterozygote advantage, Mutation, Disease, Pathology and Retinal dystrophy.
His work carried out in the field of Genetic enhancement brings together such families of science as Retinal structure, Adeno-associated virus, Bioinformatics, Compound heterozygosity and Anti vegf. His biological study spans a wide range of topics, including Retinal degeneration and Visual field. His Vitrectomy study integrates concerns from other disciplines, such as Leber's congenital amaurosis, Adverse effect, Nyctalopia and Gene mutation.
His main research concerns Retinal, Ophthalmology, Genetic enhancement, RPE65 and Visual acuity. The various areas that he examines in his Retinal study include Confocal and Retina. His research in Ophthalmology intersects with topics in Randomized controlled trial and Physical examination.
The Genetic enhancement study which covers Adeno-associated virus that intersects with Cilium, Immune system, Pathology and Ciliopathy. His work carried out in the field of RPE65 brings together such families of science as Antibody, Disease, Allele and Bioinformatics. His Visual acuity research incorporates themes from Young adult, Adverse effect and Clinical trial, Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Albert M. Maguire;Francesca Simonelli;Eric A. Pierce;Edward N. Pugh.
The New England Journal of Medicine (2008)
Gene therapy restores vision in a canine model of childhood blindness.
Gregory M. Acland;Gustavo D. Aguirre;Jharna Ray;Qi Zhang.
Nature Genetics (2001)
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
Albert M. Maguire;Albert M. Maguire;Katherine A. High;Katherine A. High;Alberto Auricchio;J. Fraser Wright;J. Fraser Wright.
The Lancet (2009)
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
Stephen Russell;Jean Bennett;Jennifer A. Wellman;Daniel C. Chung.
The Lancet (2017)
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
Samuel J Reich;Joshua Fosnot;Akiko Kuroki;Waixing Tang.
Molecular Vision (2003)
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.
Francesca Simonelli;Albert M Maguire;Albert M Maguire;Francesco Testa;Eric A Pierce.
Molecular Therapy (2010)
Long-Term Restoration of Rod and Cone Vision by Single Dose rAAV-Mediated Gene Transfer to the Retina in a Canine Model of Childhood Blindness
Gregory M. Acland;Gustavo D. Aguirre;Jean Bennett;Tomas S. Aleman.
Molecular Therapy (2005)
Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model
Alberto Auricchio;Gary Kobinger;Vibha Anand;Markus Hildinger.
Human Molecular Genetics (2001)
Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy
Jean Bennett;Teruyo Tanabe;Dexue Sun;Dexue Sun;Dexue Sun;Yong Zeng.
Nature Medicine (1996)
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Jean Bennett;Jean Bennett;Manzar Ashtari;Jennifer Wellman;Kathleen A. Marshall.
Science Translational Medicine (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: